Lipidor Dirección

Dirección controles de criterios 2/4

El CEO de Lipidor es Ola Holmlund, nombrado en Sep 2018, tiene una permanencia de 6.17 años. posee directamente un 0.045% de las acciones de la empresa, con un valor de SEK43.29K. La antigüedad media del equipo directivo y de la junta directiva es de 15.8 años y 4.8 años, respectivamente.

Información clave

Ola Holmlund

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.2yrs
Participación del CEO	0.05%
Permanencia media de la dirección	15.8yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation

May 13

Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth

Jan 29

Need To Know: Lipidor AB (publ) (STO:LIPI) Insiders Have Been Selling Shares

Dec 07

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ola Holmlund en comparación con los beneficios de Lipidor?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-SEK 14m
Mar 31 2024	n/a	n/a	-SEK 12m
Dec 31 2023	n/a	n/a	-SEK 11m
Sep 30 2023	n/a	n/a	-SEK 15m
Jun 30 2023	n/a	n/a	-SEK 25m
Mar 31 2023	n/a	n/a	-SEK 30m
Dec 31 2022	n/a	n/a	-SEK 41m
Sep 30 2022	n/a	n/a	-SEK 44m
Jun 30 2022	n/a	n/a	-SEK 28m
Mar 31 2022	n/a	n/a	-SEK 28m
Dec 31 2021	n/a	n/a	-SEK 21m
Sep 30 2021	n/a	n/a	-SEK 15m
Jun 30 2021	n/a	n/a	-SEK 23m
Mar 31 2021	n/a	n/a	-SEK 18m
Dec 31 2020	n/a	n/a	-SEK 16m
Sep 30 2020	n/a	n/a	-SEK 15m
Jun 30 2020	n/a	n/a	-SEK 14m
Mar 31 2020	n/a	n/a	-SEK 14m
Dec 31 2019	n/a	n/a	-SEK 14m
Sep 30 2019	n/a	n/a	-SEK 13m
Jun 30 2019	n/a	n/a	-SEK 10m
Mar 31 2019	n/a	n/a	-SEK 9m
Dec 31 2018	SEK 439k	SEK 300k	-SEK 8m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Ola es razonable en comparación con empresas de tamaño similar en el mercado Swedish.

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Ola con los resultados de la empresa.

CEO

Ola Holmlund (55 yo)

6.2yrs

Permanencia

SEK 439,000

Compensación

Mr. Ola Holmlund serves as the Chief Executive Officer at Lipidor AB (publ) since September 1, 2018. He served as the Head of Sales at Kibion AB. He has experience in international sales and the launch of...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ola Holmlund	Chief Executive Officer	6.2yrs	SEK 439.00k	0.045% SEK 43.3k
Olle Holmertz	Founder & Business Controller	15.8yrs	SEK 540.00k	sin datos
Anders Carlsson	Co-Founder	15.8yrs	SEK 136.00k	sin datos
Bengt Herslöf	Co-founder & Senior Scientific Advisor	15.8yrs	sin datos	sin datos
Jan Holmbäck	Co-Founder & Chief Scientific Officer	15.8yrs	sin datos	0.11% SEK 100.5k
Gerhard Miksche	Co-Founder	15.8yrs	sin datos	sin datos
Charlotta Ekman	Chief Financial Officer	2.1yrs	sin datos	sin datos
Vibhu Rinwa	Chief Operating Officer	less than a year	sin datos	0.0044% SEK 4.2k

15.8yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LIPI es experimentado (15.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunilla Lundmark	Independent Director	4.8yrs	sin datos	sin datos
Ola Flink	Independent Director	7.8yrs	SEK 31.00k	0.059% SEK 56.4k
Otto Skolling	Independent Director	4.4yrs	sin datos	sin datos
Fredrik Sjovall	Independent Chairman of the Board	6.8yrs	SEK 226.00k	0.0049% SEK 4.7k
Denis Angioletti	Independent Director	4.4yrs	sin datos	sin datos

4.8yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de LIPI se considera experimentada (4.8 años de antigüedad promedio).

Lipidor Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Lipidor AB (publ), Annual General Meeting, Jun 05, 2024

Insufficient new directors

Lipidor AB (publ), Annual General Meeting, Jun 08, 2023

Lipidor AB (Publ) Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022

Independent Chairman of the Board recently bought kr111k worth of stock

Independent Chairman of the Board recently bought kr111k worth of stock

Recent updates

New major risk - Market cap size

Lipidor AB (publ) Announces First Patient Enrolled in Phase III Study of AKP02G2 for Topical Treatment of Psoriasis

New major risk - Shareholder dilution

Lipidor AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025

Lipidor AB (publ) Announces That Clinical Trial Material for Psoriasis Candidate AKP02G2 Has Been Releases According to Plan

First quarter 2024 earnings released: EPS: kr0.011 (vs kr0.014 in 1Q 2023)

Lipidor AB (publ) to Report Fiscal Year 2023 Final Results on May 15, 2024

Lipidor AB (publ) Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2

Full year 2023 earnings released: kr0.40 loss per share (vs kr1.43 loss in FY 2022)

Lipidor Applies to the Indian Medical Products Agency to Start A Phase III study of AKP02G2

Lipidor AB (publ), Annual General Meeting, Jun 05, 2024

Lipidor AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Lipidor AB (publ) Files New Patent Application with the European Patent Office

Second quarter 2023 earnings released: kr0.13 loss per share (vs kr0.30 loss in 2Q 2022)

Insufficient new directors

Lipidor AB (Publ) Confirms Clinical Plan for New Version of Akp02

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.75 loss in FY 2021)

Lipidor AB (publ), Annual General Meeting, Jun 08, 2023

Lipidor AB (publ) to Report Nine Months, 2023 Results on Nov 22, 2023

Lipidor AB (Publ) Provides Update Following Outcome of Phase Iii Study of Psoriasis Candidate Akp02

Lipidor AB (publ) Announces Results from the Its Clinical Phase III Study of AKP02 for Psoriasis

Lipidor Updates on Phase III Clinical Study of Psoriasis Candidate AKP02

We're Hopeful That Lipidor (STO:LIPI) Will Use Its Cash Wisely

Second quarter 2022 earnings released: kr0.30 loss per share (vs kr0.26 loss in 2Q 2021)

Lipidor AB (Publ) Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022

Lipidor AB (Publ) Announces All Patients in Lipidor's Phase III Study with Psoriasis Candidate Akp02 Have Completed Treatment

Lipidor AB (publ) Announces Last Patient Has Been Enrolled in the Ongoing Phase III Study of AKP02 Against Mild to Moderate Psoriasis

Lipidor Ordinary Shares to Be Deleted from OTC Equity

Lipidor Updates on Phase III Study of AKP02 in Treatment of Psoriasis

Price target decreased to kr14.50

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Consensus EPS estimates fall by 40%

Price target decreased to kr14.50

Independent Chairman of the Board recently bought kr111k worth of stock

Independent Chairman of the Board recently bought kr111k worth of stock

Lipidor (STO:LIPI) Is In A Strong Position To Grow Its Business

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis

Lipidor AB (Publ) Expands Clinical Program, Announces Investment in New Drug Development Project Against Acne Vulgaris

No longer forecast to breakeven

Chief Executive Officer exercised options to buy kr3.7m worth of stock.

Lipidor AB (publ) Announces Approval to Start Phase III Clinical Study of Drug Candidate Akp02 for Treatment of Psoriasis

We Think Lipidor (STO:LIPI) Can Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation

New 90-day low: kr10.93

Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth

New 90-day low: kr11.98

Cannassure Therapeutics Ltd., Enters into Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano Technology

Lipidor AB and Cannassure Therapeutics Ltd Enter Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano® Technology

Lipidor AB (publ) to Report Q3, 2021 Results on Nov 17, 2021

Lipidor Signs Cooperation Agreement with Aurena Laboratories AB to Offer Licensees the Opportunity for GMP Production

Need To Know: Lipidor AB (publ) (STO:LIPI) Insiders Have Been Selling Shares

Lipidor AB (Publ) Announces Nomination Committee

Lipidor AB (publ) to Report Q1, 2021 Results on May 06, 2021

Lipidor Announces Positive Outcome of Feasibility Study for Development of Topical Medical Cannabis Products Based on the Company's Akvano® Technology

New 90-day low: kr12.55

First half earnings released

Lipidor AB (publ) to Report Q4, 2020 Results on Feb 09, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad